All companion animal practices will be presented with oncology cases on a regular basis, making diagnosis and treatment of cancer an essential part of comprehensive primary care. Because each oncology case is medically unique, these guidelines recommend a patient-specific approach consisting of the following components: diagnosis, staging, therapeutic intervention, provisions for patient and personnel safety in handling chemotherapy agents, referral to an oncology specialty practice when appropriate, and a strong emphasis on client support. Determination of tumor type by histologic examination of a biopsy sample should be the basis for all subsequent steps in oncology case management.
Introduction
Every primary-care companion animal practice will encounter its share of oncology cases. This has never been truer since improvements in pet nutrition, widespread heartworm control, renewed emphasis on age-specific preventive pet healthcare, regular vaccinations, and senior pet screenings have led to a growing population of older dogs and cats. In fact, a large-scale (n . 74,000 dogs), two-decade demographic study of the Veterinary Medical Database found that neoplastic disease was the most common terminal pathological process in 73 of 82 canine breeds and the most common cause of death in dogs .1 yr of age, with an incidence .3 times that of traumatic injury. 1 Because oncology cases are inevitable in clinical practice, some degree of expertise in diagnosis and treatment of cancer is expected by clients and is an essential component of a comprehensive primary-care veterinary practice.
The purpose of these guidelines is to provide practice teams with guidance for accurate diagnosis and optimal management of the canine and feline cancer patient. Because almost all pet owners have some acquaintance with cancer in their own lives, they will measure a veterinarian's approach to managing an oncology case against their own experience. Perhaps to a greater degree than in other clinical situations, the client plays a prominent role in directing how a pet's cancer is managed. For this reason, it is particularly important that veterinarians adopt an informed and systematic approach to managing an oncology case, including maintaining an active and empathetic dialogue with the owner in developing a treatment plan.
Every cancer case is different, even if the type of neoplasia is commonplace. For this reason, these guidelines are specific in many respects without being overly prescriptive. Within this framework, these guidelines offer the following sequential approach to managing each medically unique cancer case: diagnosis, staging, therapeutic considerations, careful attention to patient and personnel safety in handling chemotherapeutic agents, referral to an oncology specialty practice when appropriate, and a strong emphasis on client support.
Because oncology patients are frequently of an advanced age, their owners are often highly bonded to them and emotionally distraught after receiving a cancer diagnosis. Thus, a team approach emphasizing compassionate and transparent communication from clinical staff to pet owner and, in difficult cases, involving a referral center are critical factors in a satisfactory case outcome. A later section of these guidelines discusses in detail the importance of maintaining an empathetic, informed dialogue with the client, including techniques for discussing the patient's prognosis and treatment options.
Because oncology cases have the potential to create a strong bond between the practice and the owner of a pet with cancer, primary-care veterinarians should be willing to consider treating select cases. The caveat in doing so is to ensure that the healthcare team is adequately trained and equipped to appropriately manage the case. A section on safety discusses in detail the safety precautions and equipment that are appropriate when chemotherapeutic agents are used. These include the equipment needed and methods used to protect the clinic environment as well as the healthcare team, the patient, and the pet owner.
Each type of cancer and organ system involved has a particular progression to be considered when staging the case and presenting treatment options to the pet owner. A critical aspect of successful oncology case outcome is to develop a treatment plan specific for the type of tumor involved. Readers will find the two comprehensive tables on common cancers of dogs and cats to be a concise and useful resource for this purpose. The task force wishes to emphasize that the information in the tables should not be interpreted as a ''cookbook approach'' to case management but rather a compilation of relevant, tumor-specific information to help guide decision making. A sample case history is also provided so that practitioners can consider how they would use the cancer tables to assess and treat the case.
These guidelines are not intended to be overly prescriptive, for example, they do not provide chemotherapeutic dosage recommendations. Other, more complete sources of information are available for such purposes. However, these guidelines do place special emphasis on three topics of paramount importance in oncology case management: safety in handling chemotherapeutic agents, delivery of radiation therapy, and relationships with the owners of cancer patients.
As in all aspects of clinical veterinary medicine, each member of the healthcare team represents the practice as a whole. An underlying theme of these guidelines is that all staff members, including clinical and administrative personnel, can positively influence the outcome of an oncology case. A unified healthcare team that speaks with one voice will actively support a long-term relationship with a client who entrusts the practice with the care of a pet diagnosed with cancer.
Making a Referral and Working with Specialists
Practitioners who refer an oncology patient to a specialist should be mindful of the following considerations:
Each patient and case is unique.
Referral of an oncology patient is a multifactorial process that considers the patient's quality of life (pre-and postreferral) and the pet owner's preferences, emotional attachment to the animal, and the adequacy of his or her physical and financial resources to properly care for the animal. The primary care clinician, specialist, and pet owner must clinician, the specialist, and the owner.
Diagnosis of Tumor Type
Once the possibility of a neoplastic process is suspected, determination of the tumor type serves as the basis for all subsequent steps in patient management. Locally aggressive, especially injection site with high (..50% ) local recurrence. Non-injection site sarcoma is less aggressive and location-and grade-dependent. Metastatic rate is ,10% for low grade, noninjection site. Metstatic rate .25% for high grade and/or injection site sarcoma.
3-view chest radiographs 6 chest radiographs versus CT/MRI for surgical and radiation therapy planning of tumors and tumors adjacent to key anatomic structures AUS AUS, abdominal ultrasound; CNS, central nervous system; DFI, disease-free interval; MST, median survival time; NSAID, nonsteroidal anti-inflammatory drug; RT, radiotherapy. 
Therapeutic Modalities: Chemotherapy and Immunotherapy
Chemotherapy is now a commonly used treatment modality in veterinary cancer medicine. Conventional chemotherapy, metronomic chemotherapy, and targeted chemotherapy using tyrosine kinase inhibitors (TKIs) are all currently available to the small animal practitioner and differ in their indications and goals.
Therefore, in order to be successfully used in practice, the clinician must be aware of some of the basic principles of each approach.
Knowledge of the appropriate administration techniques and potential side effects of the drugs to be used is also essential and will be covered in later sections.
General Principles of Conventional Chemotherapy
Conventional chemotherapy is also known as maximally tolerated dose (MTD) chemotherapy. This refers to administration of chemotherapeutic agents at the maximum recommended dose 
Metronomic Chemotherapy
Metronomic chemotherapy is defined as the uninterrupted administration of low doses of cytotoxic drugs at regular and frequent intervals. Recent studies suggest that this approach may be at least as effective as conventional chemotherapy and is associated with less toxicity and expense. carcinoma. An assortment of other neoplasms were also evaluated (osteosarcoma, melanoma, and assorted carcinomas) but in a much smaller number of patients. [7] [8] [9] [10] [11] In the majority of these studies, the oral chemotherapy drug cyclophosphamide a was used. [8] [9] [10] Other chemotherapeutic agents that have been assessed were lomustine (also known as CCNU) and chlorambucil. 7, 11 These oral chemotherapeutics were often combined with a nonsteroidal anti-inflammatory drug (NSAID) due to the anti-angiogenic properties of the NSAID drug class. 5 Due to the generally positive responses reported in these studies, cyclophosphamide has often been used in a metronomic fashion in veterinary medicine, frequently in combination with a NSAID.
In contrast to conventional chemotherapy, the desired endpoint for metronomic chemotherapy is often stabilization of disease rather than an overall reduction in the tumor burden. 
Immunotherapy
Capturing the ability of the immune system to fight cancer holds 
Nutrition
The nutritional status of all oncology patients should be routinely assessed beginning at diagnosis and throughout treatment. 
Goals of Radiation Therapy
The goal of definitive or curative radiation therapy is eradication of all viable tumor cells within the patient. Its intent is to cure the patient whenever possible and to prolong survival as long as possible. 18 Palliative radiation is playing a larger role in 
Normal Tissue Response
Within the first few wk after the start of radiation, acute effects are typically seen in normal tissues such as bone marrow, epidermis, gastrointestinal cells, and mucosa as well as in neoplastic cells. 
Tumor-Specific Radiation Considerations

Follow-Up Care
Assessment of Response 
Maintenance Chemotherapy
For many oncology cases, initial therapy is done to prolong survival even though it is not considered curative. Additional chemotherapy, metronomic chemotherapy, or TKIs and cyclo-oxygenase inhibitors (COX-2) have been used as ongoing therapy in such cases. Use of the latter two agents is justified by their antiangiogenic properties as well as their anti-proliferative effects.
25,26
Management of Recurrent or Metastatic Disease
The concepts that apply to maintenance chemotherapy are relevant to managing recurrent or metastatic disease. Pet owners should be prepared for repeat imaging and staging prior to final treatment decisions. Assessment of the patient's quality of life is needed at this critical juncture because of the guarded prognosis and likelihood that a return to normalcy may not be possible.
Goals of therapy in such cases are often dynamic and are obviously impacted by extent of disease and expectations for the patient's quality of life. Tables 1 and 2 
Overview of Common Cancers
Case Study: Canine Osteosarcoma
The case study presented here is an example of how diagnostics and therapeutics can be used in the management of a cancer patient.
The case study is not intended be prescriptive or to imply that the approach taken here is the only way to manage an osteosarcoma patient, nor is it intended to be used as a diagnostic tree.
Practitioners interested in oncology are encouraged to research current diagnostics, chemotherapeutics, and modalities appropriate for each cancer patient as the best way of keeping current in this rapidly evolving field of veterinary medicine. The case history includes the rationale for ''decision points,'' the interventions the clinician would make in appropriately treating the patient. 
Personnel Safety Considerations
There are several routes of exposure to HDs. HDs can enter the body via inhalation, accidental injection, ingestion of contaminated foodstuffs, hand-to-oral contact, and dermal absorption. 30 tested chemotherapy gloves may be worn. 31 When administering, managing, and disposing of HDs, two pairs of ASTM-tested chemotherapy gloves may be worn. 31 The inner glove should be worn under the gown cuff and the outer glove over the cuff.
Disposable gowns made of polyethylene-coated polypropylene or other laminate materials offer the best protection. 31 Eye, face, and respiratory protection is mandatory when working with HDs outside of a clean room or isolator cabinet, or whenever there is a probability of splashing or uncontrolled aerosolization of HDs. A full face mask is a suitable alternative to goggles, although it does not form a seal or fully protect the eyes. A NIOSH N95 respirator mask is suitable for most situations, with the exception of large spills that cannot be contained by a commercially available spill kit.
PPE should be removed in the following order: chemotherapy gown (touching the outside of the gown, then rolling the outside inward to contain HD trace contamination), goggles and face shields (touching only the outside without making contact with the face), then chemotherapy gloves (touching the outside of the gloves away from the exposed skin while attempting to roll the glove outside-in).
If a glove becomes contaminated or if there is a breach in the glove, it should be removed and discarded promptly, while carefully avoiding contamination of the handler's skin or nearby surfaces.
Closed system transfer devices (CSTDs) are another type of PPE that can be used for any cytotoxic chemotherapy agent 
Environmental Safety Considerations
Environmental controls are an important part of risk mitigation.
The recommended location for chemotherapy preparation and administration is a quiet, low-traffic room that is dedicated to chemotherapy purposes, free from distractions, and easy to clean.
Because HD spill events represent the greatest risk of personnel exposure, it is important to use extreme care when cleaning spills.
Commercially available spill kits are useful in containing and cleaning HD spills. Absorbent pads or pillows can be used to immediately contain larger spills. When managing a spill, it is recommended to start from the outer edges of the spill and work your way towards the middle to prevent spreading HD residue. A HD-spill management sequence ( 
Patient Safety Considerations
Extravasations
Extravasation is the process of liquid leaking into surrounding tissue, typically near the insertion site of a peripheral catheter.
Drugs are classified according to their potential for causing damage as vesicant, irritant, or a nonvesicant. 36 
Open-End Versus Closed-End Questions
Posing open-end questions is a simple but particularly useful technique for obtaining an accurate patient history and having fruitful discussions about diagnostic results and treatment choices. 
End-of-Life Decisions
One of the options that veterinary medicine has to offer in order to alleviate pain and suffering is euthanasia. Many cancer cases will conclude with a discussion and an end-of-life decision involving the owner and a member of the healthcare team. Understandably, these discussions can be difficult. Practitioners should be prepared to help the pet owner realize that euthanasia is a humane alternative and a 
